Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03825796
Title CPX-351 Plus Enasidenib for Relapsed AML
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jonsson Comprehensive Cancer Center
Indications

acute myeloid leukemia

Therapies

CPX-351 + Enasidenib

Cytarabine + Enasidenib

Enasidenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST